The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, Genomics & Biotechnology Companies), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.
Company profile updated November 8, 2026.
As of November 6, 2026. Daily closing data may differ from the live quote shown in the dashboard.
Compare the company’s price history and fundamentals in the dashboard. Explore disclosed trading and ownership activity in these research collections: